All News
AS v nr-AxSpA for TNFi - no diff in response
@JointMD @RheumNow #RNL2024
ADA: ASAS20 AS 58%, nr-AxSpA 52%, ASAS40 AS 39%, nr 36% (ATLAS, ABILITY-1)
ETN: ASAS 20 59%/52%, ASAS50/40 44%/33% in p3 AS study v EMBARK
CZP: RAPID-AxSpA - no diff bw AS & nr-AxSpA response in same trial https://t.co/Rau2CDYbY4
Eric Dein ericdeinmd ( View Tweet)
The ultimate treatment goal in LN is long term preservation of kidney function.
Summary of part 3 of @andreafava brilliant talk.
#RNL2024
@RheumNow https://t.co/vwiAbWEmRh
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Very insightful talk on Vasculitis and pregnancy by Catherine Sims.
Pregnancy compatible medications.
Remission state.
Checking antibodies ; risk of transmission, pregnancy and fetal morbidity.
#RNL2024
@RheumNow https://t.co/81NAN1ulO5
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#RNL2024 @RheumNow
@JointMD on AxSpA
SPEED study: roughly 1/2 AS have AxSpA, 1/2 have nr-AxSpA
Are they similar:
- Yes, but r-axSpA less F and more abnml CRP
= Low progression of nr-AxSpA to AS - only 26% progressed in mean 10.6 yrs https://t.co/Vwf5HaMcgu
Links:
Eric Dein ericdeinmd ( View Tweet)
We all want to preserve kidney function in lupus nephritis and to have good none invasive method to do that is just great.
Low IL-16 at 12 months predicted kidney survival at 3 years better than proteinuria.
👏 @andreafava and his team.
#RNL2024
@RheumNow https://t.co/O0trWoAqZz
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Urine biomarkers ( IL-16, CD163,CD206), parallel internal activity in lupus nephritis and and its decline at 3 months , best predict 1 year response .
Future is great for lupus nephritis , cant wait to start using them.
Great work @andreafava
#RNL2024
@RheumNow https://t.co/VIFMytHFyD
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Urine proteomics in lupus nephritis.
Summary of part one of his amazing talk.
@andreafava
#RNL2024
@RheumNow https://t.co/h8Eda0ZWVE
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Neutrophil signature in proliferative lupus nephritis.
@andreafava
#RNL2024
@RheumNow https://t.co/tNFIhohSvP
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cancer and Myositis #RNL2024 @RheumNow
@DrLisaCS on Cancer screening:
Risk stratify: dermatomyositis, NXP2, TIFy, <40yo, refractory, dysphagia, cutaneous necrosis at higher risk
Enhanced risk stratification for those at risks, versus "basic screening" for lower risks https://t.co/3yy9Fx1pk8
Eric Dein ericdeinmd ( View Tweet)
Dr Christopher-Stine @DrLisaCS Factors which should influence (some very strongly) your cancer screening approach in myositis @RheumNow #RNL2024 https://t.co/BoyJLrVDwo
Richard Conway RichardPAConway ( View Tweet)
anti-Sp4 Ab may be protective against cancer in myositis pts who are TIF1-g positive - Dr. L Christopher-Stine #RNL2024 @rheumnow https://t.co/n7Ikn3llGH
TheDaoIndex KDAO2011 ( View Tweet)
Continue to love this myositis diagram. Seems to be getting ever more complicated though! @DrLisaCS @RheumNow #RNL2024 https://t.co/eXz6144y3y
Richard Conway RichardPAConway ( View Tweet)
Cancer and Myositis #RNL2024 @RheumNow
@DrLisaCS
Dermatomyositis risks - TIF1y is highest risk, followed by NXP2
Protective features: childhood onset, ILD, arthralgias
Cancer and myositis often present w/in 1 yr before or after
Cancer is major cause of death
Eric Dein ericdeinmd ( View Tweet)
Are we overprescribing because guidelines may be skewed to favor the pharmaceutical industry? Interesting questions posed by Dr. A Kavanaugh #RNL2024 @rheumnow https://t.co/wEwHaWNY5k
TheDaoIndex KDAO2011 ( View Tweet)
Dr. A Kavanaugh discussed Ethics #RNL2024: publication bias where positive results are likely to be published compared to those with no effects -- this is a sham study with made up data submitted to 2 different ortho journals. @rheumnow https://t.co/j6gVgA67nC
TheDaoIndex KDAO2011 ( View Tweet)
Kavanaugh on Medical Ethics
#RNL2024 @RheumNow
Bias in research for ++ outcomes leads to fudging/biased interpretations of results
Fabricated study results submitted to orthopedic journals:
- 97% acceptance for positive result, 80% for no-difference result. Bias towards +outcome https://t.co/x7JJabSs4z
Eric Dein ericdeinmd ( View Tweet)
Kavanaugh on Medical Ethics
#RNL2024 @RheumNow
How do we informed consent?
- How to fully inform pts in complex research?
- Or paternalistic to not provide detailed info
- How deep to disc risk/ben?
- Easier to study in countries w/o good SoC
Prior hx: prisoners, Nazi, Tuskegee
Eric Dein ericdeinmd ( View Tweet)
@drcassysims recommends @NIH resource: https://t.co/ebtvc2zYbE to guide lactation- updated and run by pharmacists. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
MTX and cyclophosphamide are the two drugs @DrCassySims recommends holding during breast feeding in our vasculitis patients. #RNL2024 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Do you get extra-cranial imaging in your GCA patients? #rheumtwitter #RNL2024 @RheumNow @anisha_dua @DrCassySims @philseo
Dr. Rachel Tate uptoTate ( View Tweet)